A Nutrition App for Adults Taking GLP-1 Medicines for Obesity or Type 2 Diabetes
Tests a nutrition app in adults taking GLP-1 medicines for obesity or diabetes.
Plain-language title generated from the registry record
Registry title: Dietary Insights and Nutritional Education in Adults on GLP-1 Therapy
Key facts
- Where
- Columbia, United StatesSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 65 years old?
Source: NCT07518407, who can take part
Where in United States
- University South CarolinaColumbia, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- University of South Carolina
- Trial code
- NCT07518407
- Record updated
- 23 September 2026
- Original description
This pilot study will evaluate the feasibility, acceptability, and perceived usefulness of the SWITCH mobile nutrition behavioral intervention among adults receiving GLP-1 receptor agonist therapy for obesity and/or type 2 diabetes. Participants will complete baseline assessments, receive a 6-week app-based nutrition intervention consisting of daily dietary self-monitoring and weekly learning modules, and complete follow-up assessments and a structured interview.Read full original descriptionShow less
Dietary Insights and Nutritional Education in Adults on GLP-1 Therapy
This pilot study will evaluate the feasibility, acceptability, and perceived usefulness of the SWITCH mobile nutrition behavioral intervention among adults receiving GLP-1 receptor agonist therapy for obesity and/or type 2 diabetes. Participants will complete baseline assessments, receive a 6-week app-based nutrition intervention consisting of daily dietary self-monitoring and weekly learning modules, and complete follow-up assessments and a structured interview.
Inclusion: • Age between 18 and 65 years; BMI between 30 - 49.9 kg/m2 and/or diagnosed with type 2 diabetes; Currently prescribed and using GLP-1 receptor therapy for at least 4 weeks; Own a smartphone (Android or iOS) with an active data plan to support app-based intervention delivery; Residing anywhere in the United States; Must be willing and able to reduce caloric intake; Be free of major health or psychiatric diseases, drug, or alcohol dependency; Willing to sign informed consent.
Exclusion: • Presence of type 1 diabetes mellitus; Severe complications, including but not limited to proliferative retinopathy, severe peripheral neuropathy, nephropathy requiring dialysis, active foot ulcers, or recent hospitalization for diabetic ketoacidosis or hyperosmolar hyperglycemic state within the past 6 months; Current or recent (within 6 months) participation in another structured weight loss program or clinical trial that may interfere with study outcomes; Pregnancy, breastfeeding, or plans to become pregnant during the study period; Current use of another investigational weight loss device or medication; Diagnosed eating disorders (e.g., anorexia nervosa, bulimia nervosa, binge eating disorder) or other psychiatric conditions that may affect adherence to behavioral interventions, as determined by study staff; Severe cardiovascular, hepatic, renal, or pulmonary disease that would limit participation in moderate physical activity or dietary modification; Active cancer treatment (chemotherapy, radiation, or surgery) within the past 12 months; Substance use disorder or alcohol dependency within the past 12 months; Cognitive impairment or any medical or mental condition that would interfere with the ability to understand or comply with study procedures; Lack of reliable internet or smartphone access, or unwillingness to use a mobile app for tracking and communication.